Share Facebook Twitter LinkedIn Pinterest Email ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sassy Resources Changing Name to “Sassy Gold”; Renewed Focus On Eskay Camp Foremore ProjectJuly 4, 2022
